Innate Pharma's Lacutamab Shows Clinical Responses In KIR3DL2-Expressing Mycosis Fungoides Patients

Innate Pharma SA IPHA has announced preliminary data from the mycosis fungoides (MF) cohort of the Phase 2 TELLOMAK clinical trial, evaluating lacutamab.
Data were shared at the International Conference on Malignant Lymphoma.
Lacutamab demonstrated clinical responses in patients with MF that express KIR3DL2 (cohort 2), reaching the pre-determined threshold to advance to stage 2.
As of May 10, data cutoff in the KIR3DL2-expressing cohort (n=17), complete (n=1), partial (n=3), and unconfirmed partial (n=2) global responses were observed.
Following the data cutoff, the two unconfirmed partial responses have been confirmed.
The company plans to initiate a peripheral T-cell lymphoma program for lacutamab. A Phase 1b monotherapy study is expected to start mid-year, and an investigator-sponsored combination study is expected in the second half of this year.
Lacutamab demonstrated a favorable safety profile. Mild-moderate treatment-related adverse events (AE) were observed, with one patient (out of 36) experiencing a severe AE.
No relevant skin toxicities were observed.
Innate will provide additional information on these results tomorrow in an investor event scheduled for 8:00 a.m. ET.
Price Action: IPHA shares are down 0.54% at $3.72 during the market session on the last check Tuesday.